- Reply to C. Ren et al. Journal of Clinical Oncology. 2018 Academic Article GET IT
Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: A comparison with prostate-specific antigen across five randomized phase III clinical trials.
Journal of Clinical Oncology.
Times cited: 40
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
The Lancet Oncology.
Times cited: 355